Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
Carla Damaschin, Helen Goergen, Stefanie Kreissl, Annette Plütschow, Frank Breywisch, Stephan Mathas, Julia Meißner, Martin Sökler, Max S. Topp, Vladan Vučinić, Andreas Zimmermann, Bastian von Tresckow, Michael Fuchs, Andreas Engert, Peter Borchmann, Dennis A. Eichenauer
Abstract
Patients with advanced-stage Hodgkin lymphoma (HL) receiving intensive treatment with escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) (eBEACOPP) have excellent outcomes [ 1 , 2 ]. However, late effects such as second primary malignancies (SPM) and infertility represent ongoing concerns [ 3 , 4 ]. Novel approaches using an eBEACOPP backbone, therefore, aim at reducing toxicity without compromising efficacy. The BrECAPP (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, procarbazine, prednisone) and BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) protocols were investigated in a randomized phase II study including patients with newly diagnosed advanced-stage classical HL (cHL). Both regimens combine eBEACOPP-based chemotherapy with the CD30-directed antibody-drug conjugate brentuximab vedotin (BV). Response rates were similar to standard eBEACOPP and especially the BrECADD protocol was associated with reduced acute toxicity [ 5 ].